Targeting peptide-HLA complexes for precision immunotherapy

Area of Science:

• Immunology
• Biotechnology
• Computational Biology

Background:

• Precision immunotherapy aims to eliminate abnormal cells using the immune system.
• Targeting peptide-human leukocyte antigen (pHLA) complexes offers specific intervention due to minimal expression in healthy tissues.
• Designing highly specific pHLA binders with low cross-reactivity remains a significant challenge.

Purpose of the Study:

• To review current approaches and emerging technologies in pHLA-targeted immunotherapies.
• To discuss mechanisms, preclinical, and clinical data for pHLA-based therapeutics.
• To highlight the role of AI and computational design in advancing pHLA-targeted treatments.

Main Methods:

• T-cell receptor (TCR) mimic antibodies (TCRm) and de novo pHLA binder design.
• Development of T cell engagers and adoptive cell therapies.
• Application of artificial intelligence (AI), immunopeptidomics, and computational protein design.

Main Results:

• Synthetic approaches like TCRm and de novo binders show promising specificity and efficacy.
• AI-driven methods and computational design accelerate the discovery of pHLA therapeutics.
• Emerging technologies are enabling pan-allelic development of pHLA-targeted therapies.

Conclusions:

• pHLA-targeted immunotherapies represent a promising frontier in treating cancer, autoimmune, and infectious diseases.
• Continued advances in synthetic biology and AI are crucial for realizing the full potential of these therapies.
• The field is rapidly evolving, with significant preclinical and clinical data emerging.